2022
DOI: 10.2217/fon-2021-1261
|View full text |Cite
|
Sign up to set email alerts
|

Atezolizumab and Bevacizumab with Transarterial Chemoembolization in Hepatocellular Carcinoma: The DEMAND Trial Protocol

Abstract: The combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF bevacizumab is the first approved immunotherapeutic regimen for first-line therapy in patients with unresectable hepatocellular carcinoma (HCC), currently approved in more than 80 countries. The efficacy and tolerability of this regimen suggest that the use of atezolizumab + bevacizumab could be extended to the treatment of patients with intermediate-stage HCC in combination with transarterial chemoembolization (TACE). The authors descri… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
12
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 24 publications
(12 citation statements)
references
References 47 publications
0
12
0
Order By: Relevance
“… 24 Based on such theory and encouraged by the success of RCTs for PD-(L)1 inhibitors combined with targeted agents, many clinical trials on TACE with PD-(L)1 treatment plus MTT are in progress to verify the potential synergetic effect. 25 , 26 Unfortunately, none of such combination therapies with a large sample size have been reported by now.…”
Section: Introductionmentioning
confidence: 99%
“… 24 Based on such theory and encouraged by the success of RCTs for PD-(L)1 inhibitors combined with targeted agents, many clinical trials on TACE with PD-(L)1 treatment plus MTT are in progress to verify the potential synergetic effect. 25 , 26 Unfortunately, none of such combination therapies with a large sample size have been reported by now.…”
Section: Introductionmentioning
confidence: 99%
“…In combination with immunotherapy, TACE is proven to be clinically beneficial [ 44 ]. Studies are currently being conducted on the usage of TACE with a combination of atezolizumab-bevacizumab in patients with HCC [ 45 ].…”
Section: Reviewmentioning
confidence: 99%
“…To our knowledge, whether additional TACE treatment yields survival bene ts compared to systemic therapy for the speci c group of patients with HCC invading the MPV is still unclear. This is because these recently published cohort studies consist of a mixed group of patients with the presence of different portal vein invasion; some studies exclude the subgroup of patients with MPV invasion [11,12,25,26]. Therefore, we performed this study to compare the e cacy and safety of systemic therapy with or without TACE for patients with HCC and MPV invasion.…”
Section: Introductionmentioning
confidence: 99%